Massimiliano Mazzone

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1832480/publications.pdf

Version: 2024-02-01

149 papers	17,204 citations	22099 59 h-index	14702 127 g-index
156 all docs	156 docs citations	156 times ranked	24101 citing authors

#	Article	IF	Citations
1	Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. Cancer Immunology Research, 2022, 10, 126-141.	1.6	9
2	The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis. PLoS Pathogens, 2022, 18, e1010247.	2.1	1
3	Repression of hypoxia-inducible factor-1 contributes to increased mitochondrial reactive oxygen species production in diabetes. ELife, 2022, 11, .	2.8	31
4	Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia. EMBO Reports, 2022, 23, e53746.	2.0	26
5	PHGDH heterogeneity potentiates cancerÂcell dissemination and metastasis. Nature, 2022, 605, 747-753.	13.7	77
6	Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nature Metabolism, 2022, 4, 693-710.	5.1	49
7	A cannabidiol aminoquinone derivative activates the PP2A/B55Î±/HIF pathway and shows protective effects in a murine model of traumatic brain injury. Journal of Neuroinflammation, 2022, 19, .	3.1	8
8	Metabolic traits ruling the specificity of the immune response in different cancer types. Current Opinion in Biotechnology, 2021, 68, 124-143.	3.3	4
9	Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and Glycogenesis. Cell Metabolism, 2021, 33, 411-423.e4.	7.2	84
10	MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment. Cancers, 2021, 13, 127.	1.7	11
11	Differential Effects of Trp53 Alterations in Murine Colorectal Cancer. Cancers, 2021, 13, 808.	1.7	5
12	BNIP3 promotes HIFâ€1Î±â€driven melanoma growth by curbing intracellular iron homeostasis. EMBO Journal, 2021, 40, e106214.	3.5	38
13	Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia. Cell Death and Disease, 2021, 12, 435.	2.7	8
14	How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications. Trends in Immunology, 2021, 42, 401-417.	2.9	18
15	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. Science Advances, 2021, 7, .	4.7	26
16	Protein Phosphatase 2A Mediates YAP Activation in Endothelial Cells Upon VEGF Stimulation and Matrix Stiffness. Frontiers in Cell and Developmental Biology, 2021, 9, 675562.	1.8	15
17	Tumor vessel co-option probed by single-cell analysis. Cell Reports, 2021, 35, 109253.	2.9	44
18	Isolation and separation of murine tumor-associated macrophages (TAMs) subpopulations from orthotopic 4T1 breast tumors. STAR Protocols, 2021, 2, 100481.	0.5	2

#	Article	IF	Citations
19	ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3. Cancer Letters, 2021, 510, 13-23.	3.2	4
20	N â€acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages. EMBO Reports, 2021, 22, e51981.	2.0	22
21	Leptin brain entry via a tanycytic LepRâ€“EGFR shuttle controls lipid metabolism and pancreas function. Nature Metabolism, 2021, 3, 1071-1090.	5.1	67
22	Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1Î± Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2. Neurotherapeutics, 2021, 18, 1849-1861.	2.1	9
23	IL1Î² Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. Cancer Immunology Research, 2021, 9, 309-323.	1.6	48
24	Immunity, Hypoxia, and Metabolismâ€“the MÃ©nage Ã Trois of Cancer: Implications for Immunotherapy. Physiological Reviews, 2020, 100, 1-102.	13.1	190
25	Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development. Cancers, 2020, 12, 3582.	1.7	23
26	DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. Genome Biology, 2020, 21, 182.	3.8	39
27	Macrophage-derived glutamine boosts satellite cells and muscle regeneration. Nature, 2020, 587, 626-631.	13.7	119
28	Understanding Metal Dynamics Between Cancer Cells and Macrophages: Competition or Synergism?. Frontiers in Oncology, 2020, 10, 646.	1.3	26
29	B55Î±/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling. Circulation Research, 2020, 127, 707-723.	2.0	24
30	Neutrophilic HGF-MET Signalling Exacerbates Intestinal Inflammation. Journal of Crohn's and Colitis, 2020, 14, 1748-1758.	0.6	12
31	Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. Cancer Immunology, Immunotherapy, 2020, 69, 1673-1697.	2.0	38
32	Editorial: Macrophage Metabolism and Immune Responses. Frontiers in Immunology, 2020, 11, 1078.	2.2	4
33	An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. Cancer Cell, 2020, 37, 21-36.e13.	7.7	253
34	Impact of Immunometabolism on Cancer Metastasis: A Focus on T Cells and Macrophages. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037044.	2.9	10
35	Glufosinate constrains synchronous and metachronous metastasis by promoting antiâ€tumor macrophages. EMBO Molecular Medicine, 2020, 12, e11210.	3.3	29
36	PoEMs edit breast cancer outcome. Aging, 2020, 12, 4045-4047.	1.4	2

#	Article	IF	Citations
37	Role and therapeutic potential of dietary ketone bodies in lymph vessel growth. Nature Metabolism, 2019, 1, 666-675.	5.1	45
38	Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. Cell Reports, 2019, 28, 104-118.e8.	2.9	67
39	Blood Vessel Proximity Shapes Cancer Cell Metabolism. Cell Metabolism, 2019, 30, 16-18.	7.2	9
40	Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. Cell Metabolism, 2019, 30, 917-936.e10.	7.2	150
41	Hypoxic cancerâ€“associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Science Signaling, 2019, 12, .	1.6	83
42	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Research, 2019, 79, 4196-4210.	0.4	53
43	Tumor-associated macrophages: a short compendium. Cellular and Molecular Life Sciences, 2019, 76, 1447-1458.	2.4	71
44	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. Cancer Research, 2019, 79, 1938-1951.	0.4	58
45	Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. Annual Review of Physiology, 2019, 81, 535-560.	5.6	44
46	Caspase-8 modulates physiological and pathological angiogenesis during retina development. Journal of Clinical Investigation, 2019, 129, 5092-5107.	3.9	16
47	Hypoxia Inducible Factor Activation Prevents Renal Mitochondria Dysfunction and Improves Cortical Oxygenation in Type 1 Diabetic Mice. FASEB Journal, 2019, 33, lb591.	0.2	0
48	Metabolism and <scp>TAM</scp> functionsâ€”it takes two to tango. FEBS Journal, 2018, 285, 700-716.	2.2	73
49	Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?. JAMA Oncology, 2018, 4, 131.	3.4	1
50	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications, 2018, 9, 4112.	5.8	55
51	Neutrophils enhance early Trypanosoma brucei infection onset. Scientific Reports, 2018, 8, 11203.	1.6	33
52	Quiescent Endothelial Cells Upregulate Fatty Acid Î²-Oxidation for Vasculoprotection via Redox Homeostasis. Cell Metabolism, 2018, 28, 881-894.e13.	7.2	174
53	Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation. Cell Metabolism, 2018, 28, 866-880.e15.	7.2	154
54	The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Seminars in Cancer Biology, 2018, 52, 107-116.	4.3	57

#	Article	IF	Citations
55	<scp>SLC</scp>25A26 overexpression impairs cell function via mt<scp>DNA</scp> hypermethylation and rewiring of methyl metabolism. FEBS Journal, 2017, 284, 967-984.	2.2	33
56	The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1Î± Levels and Colorectal Cancer Cell Survival under Hypoxia. Cell Reports, 2017, 18, 1699-1712.	2.9	88
57	Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 2017, 8, 14206.	5.8	81
58	Hypoxia determines survival outcomes of bacterial infection through HIF-1Î±â€“dependent reprogramming of leukocyte metabolism. Science Immunology, 2017, 2, .	5.6	61
59	PHD2 Targeting Overcomes Breast Cancer Cell Death upon Glucose Starvation in a PP2A/B55Î±-Mediated Manner. Cell Reports, 2017, 18, 2836-2844.	2.9	24
60	MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. Molecular Cancer, 2017, 16, 55.	7.9	12
61	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017, 47, 789-802.e9.	6.6	207
62	Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. EMBO Molecular Medicine, 2017, 9, 1629-1645.	3.3	54
63	Retinoid X receptor suppresses a metastasis-promoting transcriptional program in myeloid cells via a ligand-insensitive mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10725-10730.	3.3	24
64	Î±-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nature Immunology, 2017, 18, 985-994.	7.0	715
65	Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Reports, 2017, 20, 1654-1666.	2.9	258
66	Loss of Caveolin-1 in Metastasis-Associated Macrophages Drives Lung Metastatic Growth through Increased Angiogenesis. Cell Reports, 2017, 21, 2842-2854.	2.9	46
67	Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. EMBO Journal, 2017, 36, 2373-2389.	3.5	144
68	Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells. Antioxidants and Redox Signaling, 2017, 26, 351-363.	2.5	61
69	Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. Oncotarget, 2017, 8, 93688-93703.	0.8	7
70	Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. Journal of Clinical Investigation, 2017, 127, 3407-3420.	3.9	71
71	MIF-Mediated Hemodilution Promotes Pathogenic Anemia in Experimental African Trypanosomosis. PLoS Pathogens, 2016, 12, e1005862.	2.1	20
72	The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nature Communications, 2016, 7, 13720.	5.8	217

#	Article	IF	Citations
73	Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. European Heart Journal, 2016, 37, 2993-2997.	1.0	40
74	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature, 2016, 537, 63-68.	13.7	521
75	FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Scientific Reports, 2016, 6, 33453.	1.6	168
76	Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis. Cell Metabolism, 2016, 24, 701-715.	7.2	352
77	Vessel Normalization in the Spot-LIGHT of Cancer Treatment. Trends in Molecular Medicine, 2016, 22, 85-87.	3.5	4
78	Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut, 2016, 65, 990-1000.	6.1	67
79	The impact of hypoxia on tumor-associated macrophages. Journal of Clinical Investigation, 2016, 126, 3672-3679.	3.9	401
80	<scp>PHD</scp> 1 regulates p53â€mediated colorectal cancer chemoresistance. EMBO Molecular Medicine, 2015, 7, 1350-1365.	3.3	43
81	Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma. Oncotarget, 2015, 6, 36418-36425.	0.8	40
82	Semaphorin7A regulates neuroglial plasticity in the adult hypothalamic median eminence. Nature Communications, 2015, 6, 6385.	5.8	105
83	MET is required for the recruitment of anti-tumoural neutrophils. Nature, 2015, 522, 349-353.	13.7	359
84	The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. Cell Reports, 2015, 12, 992-1005.	2.9	66
85	Factorâ€inhibiting HIFâ€1 (FIHâ€1) is required for human vascular endothelial cell survival. FASEB Journal, 2015, 29, 2814-2827.	0.2	27
86	Identification of a chronic nonâ€neurodegenerative microglia activation state in a mouse model of peroxisomal Î²â€oxidation deficiency. Glia, 2015, 63, 1606-1620.	2.5	45
87	Functional MMPâ€10 is required for efficient tissue repair after experimental hind limb ischemia. FASEB Journal, 2015, 29, 960-972.	0.2	19
88	Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Oncotarget, 2015, 6, 11295-11309.	0.8	30
89	Sixty shades of oxygen-an attractive opportunity for cancer immunotherapy. Annals of Translational Medicine, 2015, 3, 187.	0.7	2
90	Oxygen Signaling in Physiological and Pathological Angiogenesis. , 2015, , 329-349.		0

#	Article	IF	Citations
91	Prolyl hydroxylase domain 1 (PHD1) to mediate chemoresistance in colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14534-e14534.	0.8	0
92	Immune response triggered by a novel molecular crosstalk of major hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways.. Journal of Clinical Oncology, 2015, 33, 11054-11054.	0.8	1
93	The Anti-Proliferative Effect of L-Carnosine Correlates with a Decreased Expression of Hypoxia Inducible Factor 1 alpha in Human Colon Cancer Cells. PLoS ONE, 2014, 9, e96755.	1.1	51
94	Brain Endothelial Cells Control Fertility through Ovarian-Steroidâ€“Dependent Release of Semaphorin 3A. PLoS Biology, 2014, 12, e1001808.	2.6	56
95	The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2014, 6, 567-568.	3.3	0
96	Altering the intratumoral localization of macrophages to inhibit cancer progression. OncoImmunology, 2014, 3, e27872.	2.1	9
97	Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population. Cancer Research, 2014, 74, 24-30.	0.4	348
98	Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization. Journal of Clinical Investigation, 2014, 124, 4335-4350.	3.9	46
99	Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes. PLoS ONE, 2014, 9, e107483.	1.1	17
100	Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Oncotarget, 2014, 5, 12978-12989.	0.8	34
101	Endothelial Cell Reactions to Oxygen: Implications for Cancer. , 2014, , 267-282.		0
102	Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity. Cancer Cell, 2013, 24, 695-709.	7.7	505
103	Tanycytic VEGF-A Boosts Blood-Hypothalamus Barrier Plasticity and Access of Metabolic Signals to the Arcuate Nucleus in Response to Fasting. Cell Metabolism, 2013, 17, 607-617.	7.2	285
104	Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties. Cancer Cell, 2013, 23, 477-488.	7.7	138
105	Renal CD133+/CD73+ Progenitors Produce Erythropoietin under Hypoxia and Prolyl Hydroxylase Inhibition. Journal of the American Society of Nephrology: JASN, 2013, 24, 1234-1241.	3.0	21
106	The Fragile X Protein binds m <scp>RNA</scp> s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2013, 5, 1523-1536.	3.3	106
107	PHD2 regulates arteriogenic macrophages through TIE2 signalling. EMBO Molecular Medicine, 2013, 5, 843-857.	3.3	40
108	The â€œcord of lifeâ€•serving antiangiogenic therapy. Blood, 2013, 121, 4254-4255.	0.6	0

#	Article	IF	Citations
109	Overcoming Resistance to Antiangiogenic Therapies. Oncologist, 2012, 17, 1039-1050.	1.9	53
110	Genetic Deficiency in Plasma Protein HRG Enhances Tumor Growth and Metastasis by Exacerbating Immune Escape and Vessel Abnormalization. Cancer Research, 2012, 72, 1953-1963.	0.4	32
111	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncology, The, 2012, 13, 724-733.	5.1	174
112	Loss of the Oxygen Sensor PHD3 Enhances the Innate Immune Response to Abdominal Sepsis. Journal of Immunology, 2012, 189, 1955-1965.	0.4	70
113	miR-511-3p Modulates Genetic Programs of Tumor-Associated Macrophages. Cell Reports, 2012, 1, 141-154.	2.9	193
114	Gene-Targeting of Phd2 Improves Tumor Response to Chemotherapy and Prevents Side-Toxicity. Cancer Cell, 2012, 22, 263-277.	7.7	117
115	Tumour growth inhibition and antiâ€metastatic activity of a mutated furinâ€resistant Semaphorin 3E isoform. EMBO Molecular Medicine, 2012, 4, 234-250.	3.3	82
116	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature, 2011, 479, 122-126.	13.7	265
117	Semaphorin Signals on the Road of Endothelial Tip Cells. Developmental Cell, 2011, 21, 189-190.	3.1	24
118	Growing tumor vessels: More than one way to skin a cat â€“ Implications for angiogenesis targeted cancer therapies. Molecular Aspects of Medicine, 2011, 32, 71-87.	2.7	92
119	HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF. Cancer Cell, 2011, 19, 31-44.	7.7	628
120	Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 741-749.	1.1	105
121	Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nature Reviews Clinical Oncology, 2011, 8, 393-404.	12.5	252
122	Sema3Eâ€“Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. Journal of Clinical Investigation, 2011, 121, 2945-2945.	3.9	0
123	Role of Delta-like-4/Notch in the Formation and Wiring of the Lymphatic Network in Zebrafish. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1695-1702.	1.1	118
124	Impaired Autonomic Regulation of Resistance Arteries in Mice With Low Vascular Endothelial Growth Factor or Upon Vascular Endothelial Growth Factor Trap Delivery. Circulation, 2010, 122, 273-281.	1.6	37
125	Antiâ€“Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation. Cancer Research, 2010, 70, 6537-6547.	0.4	47
126	Loss or Silencing of the PHD1 Prolyl Hydroxylase Protects Livers of Mice Against Ischemia/Reperfusion Injury. Gastroenterology, 2010, 138, 1143-1154.e2.	0.6	108

#	Article	IF	Citations
127	Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. Cell, 2010, 141, 178-190.	13.5	243
128	Sema3Eâ€“Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. Journal of Clinical Investigation, 2010, 120, 2684-2698.	3.9	157
129	Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited. Cancer Cell, 2009, 15, 167-170.	7.7	360
130	Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nature Reviews Clinical Oncology, 2009, 6, 315-326.	12.5	195
131	Role and Therapeutic Potential of VEGF in the Nervous System. Physiological Reviews, 2009, 89, 607-648.	13.1	385
132	Regulation of Angiogenesis by Oxygen and Metabolism. Developmental Cell, 2009, 16, 167-179.	3.1	361
133	Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization. Cell, 2009, 136, 839-851.	13.5	727
134	Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology, 2008, 47, 2010-2025.	3.6	15
135	A lifeline for suffocating tissues. Nature, 2008, 453, 1194-1195.	13.7	19
136	Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nature Genetics, 2008, 40, 170-180.	9.4	433
137	FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nature Reviews Cancer, 2008, 8, 942-956.	12.8	504
138	â€œActiveâ€•Cancer Immunotherapy by Anti-Met Antibody Gene Transfer. Cancer Research, 2008, 68, 9176-9183.	0.4	36
139	The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. Journal of Experimental Medicine, 2008, 205, 1155-1171.	4.2	87
140	Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11412-11417.	3.3	38
141	The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo. Clinical Cancer Research, 2007, 13, 2191-2198.	3.2	29
142	Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels. Cell, 2007, 131, 463-475.	13.5	722
143	Building in resistance to endothelial cell death. Nature Genetics, 2007, 39, 1308-1309.	9.4	3
144	Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5090-5095.	3.3	147

#	Article	IF	Citations
145	The Met pathway: master switch and drug target in cancer progression. FASEB Journal, 2006, 20, 1611-1621.	0.2	117
146	Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 2004, 6, 61-73.	7.7	282
147	An uncleavable form of proâ€“scatter factor suppresses tumor growth and dissemination in mice. Journal of Clinical Investigation, 2004, 114, 1418-1432.	3.9	85
148	Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3, 347-361.	7.7	1,244
149	An HGFâ€“MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nature Biotechnology, 2002, 20, 488-495.	9.4	22